RCA 101
Alternative Names: COG-101; RCA-101; RNA Cognitive Advantage - CognigenicsLatest Information Update: 23 Jul 2025
At a glance
- Originator Cognigenics
- Class Anxiolytics; Gene therapies; Nootropics; RNA
- Mechanism of Action 5-HT2A serotonin receptor expression inhibitors; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anxiety disorders
- Research Cognition disorders; Generalised anxiety disorder
Most Recent Events
- 23 Jul 2025 Early research in Cognition disorders in USA (Intranasal), prior to July 2025 (Cognigenics pipeline, July 2025)
- 23 Jul 2025 Early research in Generalised anxiety disorder in USA (Intranasal), prior to July 2025 (Cognigenics pipeline, July 2025)
- 27 Jun 2023 Cognigenics intends to file an IND application with the US FDA in US for Anxiety in 2024 (Cognigenics website, June 2023)